Table 1 Baseline characteristics
Number of available data | ||
|---|---|---|
Median age, years (range) | 57 (25–82) | 67 |
Male gender, n | 36 | 67 |
Body mass index, median (range) | 23.7 (13.2–33) | 64 |
Performance status (ECOG), n | 67 | |
0–1 | 62 | |
2 | 5 | |
Functioning tumour, n | 38 | 67 |
Primary lesion | ||
Pancreatic location, n | 19 | 67 |
Diameter (cm), median (range) | 3 (0.8–16) | 51 |
Resected, n | 43 | 67 |
Extra-hepatic lesion(s), n | 26 | 67 |
Indication of treatment, n | 67 | |
Progressive disease | 41 | |
Aggressive disease | 9 | |
Uncontrolled hormone-related symptoms | 17 | |
Previous chemotherapy, n | 19 | 67 |
Concomitant treatment with somatostatin analogs, n | 25 | 67 |
MIB-1 (%), median (range) | 3 (1–60) | 34 |
Radiological features of metastases | ||
Longest diameter (cm), n | 4 (1–14) | 67 |
% of liver replaced by metastases, n | 67 | |
<25% | 29 | |
>25 and <50% | 14 | |
>50 and <75% | 12 | |
>75% | 12 | |
Arterial phase enhancement, n | 42 | 61 |
Heterogeneous pattern, n | 45 | 62 |
Cytotoxic agent, n | 67 | |
Streptozotocin | 44 | |
Doxorubicin | 23 |
